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Laminin-332 is major component of epithelial basement membrane, and has an important role in cell migration and tumour invasion.
Recently, the phosphatidylinositol 3-kinase (PI3K) activation induced by laminin-332 during carcinogenesis or tumour invasion has
been highlighted in skin squamous cell carcinoma. The expression of laminin-332 in 126 resected oesophageal squamous cell
carcinoma (ESCC) specimens was immunohistochemically examined to determine its associations with the clinicopathological
characteristics, and the effect of laminin-332 on the invasiveness and the PI3K activation was assessed by in vitro experiments using
ESCC cell lines (ESCCs). Sections with immunostaining signals in 430% cancer cells, which were observed in 55 of 126 cases, were
judged to be positive for laminin-332. The positivity was significantly correlated with pTNM stage and poor prognosis. Inactivation of
the PI3K pathway by laminin-332 blocking antibody suppressed the invasiveness of TE8 cell line, which secreted laminin-332 at high
level and had high PI3K activity. The addition of the purified laminin-332 activated the PI3K pathway and increased the invasiveness of
TE11 cell line, which secreted laminin-332 at lower level and had low PI3K activity. The deactivation of PI3K pathway using the PI3K
inhibitor decreased the invasiveness of ESCCs and the secretion of laminin-332 in vitro. The expression of laminin-332 was one of the
prognostic factors of ESCC. Laminin-332 could provide the autocrine positive-feedback loop through PI3K activation, contributing
the invasive ability. Therefore, the inhibitor of PI3K pathway might be useful as the anticancer therapies for ESCC.
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Laminins are the best-known member of a family of the basement
membrane (BM) protein, and they are important in cell growth,
differentiation, adhesion and migration. The laminin molecule is a
cross-shaped heterotrimer consisting of one heavy a chain and two
light chains, b and g chains (Timpl, 1989; Beck et al, 1990;
Yurchenco and Schittny, 1990; Engle, 1992). To date, 16 laminin
isoforms with different contributions of a1–a5, b1–b3, g1–g3
chains have been identified (Miyazaki, 2006; Marinkovich, 2007).
Each laminin chain contains many functional domains, allowing
the laminins to interact with various molecules in the extracellular
matrix. For example, laminin a chains (a1–a5) contain large
globular G domains in their C terminus, which is divided into five
homologous subdomains (G1–G5). The G domain is thought to be
a major site of interaction with specific receptors on the cell
surface, including integrins, syndecans and a-dystroglycan. The
N-terminal region of the three chains contains functional domains
that are mainly involved in matrix assembly (Timpl, 1989; Beck
et al, 1990; Yurchenco and Schittny, 1990; Engle, 1992).
Laminin-332 (previously known as laminin-5), which comprises
a3, b3 and g2 chains, is a major component of epithelial BM, acts
as an adhesion substrate for the epithelial cells and regulates
epithelial cell migration during epithelial regeneration and repair
processes in normal tissues (Carter et al, 1991; Rousselle et al,
1991; Ryan et al, 1996). Laminin-332 interacts with two major
epithelial integrin a3b1 and a6b4, and promotes the formation of
two separate types of attachment structure, focal adhesion and
stable anchoring contacts (Carter et al, 1990). In several types of
carcinomas, laminin-332 has been reported to be highly expressed
and to correlate well with poor patient prognosis (Pyke et al, 1995;
Soini et al, 1996; Koshikawa et al, 1999; Matta et al, 1999; Ono et al,
1999; Yamamoto et al, 2001; Fukai et al, 2005). Laminin-332 is
known to support cellular survival, proliferation and migration by
activating many signal mediators through the ligation with a3b1
and a6b4 integrin, and to have important roles in tumour invasion
and metastasis (Nguyen et al, 2000; Kariya and Miyazaki, 2004;
Nikolopoulos et al, 2005). Particularly, the phosphatidylinositol
3-kinase (PI3K) activation induced by laminin-332 during carcino-
genesis or tumour invasion has been highlighted (Marinkovich,
2007; Waterman et al, 2007). Marinkovich has demonstrated that
the interaction of laminin-332 with a6b4 integrin and epidermal
growth factor receptor (EGFR) was involved in promoting the
PI3K activation and tumour invasion (Marinkovich, 2007).
Oesophageal squamous cell carcinoma (ESCC) is one of the
most aggressive malignant tumours, and the prognosis of ESCC is
worse than that of other digestive tract carcinomas (Enzinger and
Mayer, 2003). As to ESCC, there are two papers demonstrating that
the immunohistochemically increased cytoplasmic expression of
laminin-332 is correlated with poor prognosis (Yamamoto et al,
2001; Fukai et al, 2005). However, to our knowledge, there are no
Received 19 November 2007; revised 15 January 2008; accepted 16
January 2008; published online 19 February 2008
*Correspondence: Dr H Baba;
E-mail: hdobaba@kumamoto-u.ac.jp
British Journal of Cancer (2008) 98, 974–980
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sdata showing the relationship between laminin-332 and cancer cell
invasiveness, using oesophageal squamous cancer cell lines
(ESCCs).
The aims of this study are (1) to investigate the immunohisto-
chemical expression of laminin-332 in ESCC and to evaluate the
relationships between the clinicopathological characteristics and
survival, and (2) to examine the biological role and the signalling
pathway of laminin-332 using ESCCs.
MATERIALS AND METHODS
Patients
The present study involved 126 consecutive patients with ESCC
who underwent the curative surgical resection at Kumamoto
University Hospital from January 1997 to December 2006. All of
these patients underwent an oesophagectomy with lymph node
dissection. None of these patients underwent endoscopic mucosal
resection, palliative resection, preoperative chemotherapy or
radiotherapy, and none of them had synchronous or metachro-
nous multiple cancers in other organs. Clinical data, including age,
sex, tumour location, lymph node metastasis, T classification
(Sobin and Wittekind, 2002), TNM stage (Sobin and Wittekind,
2002) and histological grading (Hamilton and Aaltonen, 2000),
were available for all 126 patients. Patients were periodically (every
1–3 months) examined on an outpatient basis to make sure they
did not have disease recurrence. The mean follow-up period for the
126 patients was 29.6 months (range, 1–110 months). Informed
consent for the research was obtained from each patient. The study
design was approved by the ethic review board of our university.
Immunohistochemistry
Sections of 5mm in thickness were dewaxed in xylene and
rehydrated in ethanol and then heated to 1321C in an autoclave
for 5min in 10nmoll
 1 citrate buffer (PH 6.3). The endogenous
peroxidase activity was suppressed by a solution of 3% hydrogen
peroxide in methanol for 60min. The sections were immersed in
5% normal horse serum in PBS for 30min, covered with mouse
anti-laminin g2 chain (1:200, Chemicon, Billerica, USA), and
incubated overnight at 41C. Negative controls were stained with
PBS and normal mouse IgG instead of the primary antibody.
Immunoreactions were performed using a Vecstatin peroxidase
ABC kit (Vector Laboratories, Peterborough, UK). The antigenic
sites were demonstrated by reacting the sections with a mixture of
0.05% 3,3-diaminobenzidine tetrahydrochloride (Dojindo Chemicals,
Dojindo Laboratories, Kumamoto, Japan) in 0.05% moll
 1 Tris-HCl
buffer, pH 7.6, containing 0.01% H2O2 for 5min. The nuclei were
stained with haematoxyline.
Sections with immunohistochemical staining in 430% of
carcinoma cells at the invasive front were judged to be positive
for laminin-332 as with the previous reports (Yamamoto et al,
2001; Fukai et al, 2005). The staining assessment was indepen-
dently carried out by two of the authors (KI and YB) without any
knowledge of either the clinical or survival data.
Cell culture
ESCCs were obtained from Cell Resource Center for Biomedical
Research, Tohoku University, Japan. Cell cultures were grown in
recommended medium with 10% fetal bovine serum (FBS) and
incubated in 5% CO2 at 371C.
Antibodies and other reagents
Antibodies for western blot analysis were as follows: rabbit anti-
phospho Akt, rabbit anti-Akt (Cell Signaling Technology,
Danvers, USA), mouse anti-laminin g2 chain (Chemicon), mouse
anti-epidermal growth factor receptor (ZYMED Laboratories, San
Francisco, USA), mouse anti-integrin b4 (Santa Cruz Biotechnol-
ogy, Santa Cruz, USA). Anti-laminin g2 antibody (Chemicon) was
used as the blocking antibody as with previous article (Decline and
Rousselle, 2001). The purified human laminin-332 was purchased
from Biodesign Internatinal, and the PI3K inhibitor Wortmannin
was purchased from Santa Cruz Biotechnology.
Western blot analysis
Cultured cells were solubilised with the lysis buffer (Tris-HCl
(pH7.4). 25mM, NaCl 100mM, EDTA 2mM, TritonX 1% with
10mgml
 1 Aprotinin, 10mgml
 1 Leupeptin, 1mM Na3VO4, 1m M
PMSF). To evaluate the secreted laminin-332 in the cell culture
medium, each cell line was plated at 1 10
6 cells per 100-mm
culture dish in serum-free medium. Conditioned medium was
collected at 24h. 10mg of each protein sample was mixed with 4 
sample buffer including 10% b-mercaptoethanol and boiled 5min.
Next, equal amount of samples were separated on 7.5% (for the
reduced laminin-332), 6.0% (for the non-reduced laminin-332) or
12% (for others) SDS–polyacrylamide gels and transferred to
PVDF membranes. The membranes were probed with each
primary antibody overnight at room temperature, followed by a
1:1000 dilution of peroxidase-conjugated IgG antibody (Sigma,
St Louis, USA). Detection was accomplished with an ECL reagent
(Amersham, Buckinghamshire, UK).
To evaluate the relationship between the secretion of laminin-
332 and the PI3K pathway, the confluent cells were incubated with
the PI3K inhibitor (Wortmannin) at different concentration for
24h, and the culture medium was collected. Equal amount of
samples were separated on 7.5% SDS–polyacrylamide gel and
transferred to PVDF membranes.
Cell-invasion assay
In vitro cell invasion assay was conducted using Biocoat Matrgel
Invasion Chambers (BD Biosciences Discovery Labware, Franklin,
USA) according to the manufacturer’s protocols. After detaching the
cells in 0.25% trypsin and counting, cells were diluted to 100000
cells per ml in medium counting 0.5% FBS. A total of 500ml of cells
were then placed in quintuple in the top chamber of the insert
above medium counting 10% FBS, and were incubated in 371C, 5%
CO2 for 22h. Next, the cells on the upper surface of the membrane
were removed with a cotton swab, and the migrated cells on the
underside of the membrane were fixed and stained using toluidine
blue and counted in five random fields at  200 magnification.
To examine the effects of the purified laminin-332, anti-laminin-
332 blocking antibody and the PI3K inhibitor (Wortmannin) on
the invasiveness of ESCCs, the purified laminin-332 (0.5mgml
 1),
anti-laminin-332 blocking antibody (40mgml
 1) or the PI3K
inhibitor (Wortmannin; 100nM) was added into the top chamber.
As controls, the purified albumin (0.5mgml
 1) or anti-IgG
antibody (40mgml
 1) was used.
Statistical analysis
Laminin-332 expression in ESCC was assessed to identify any
associations with clinicopathological parameters using w
2 two-
tailed test or Fisher’s exact test. The disease-free survival and
overall cancer-specific survival curves were constructed using the
Kaplan–Meier method, and the log-rank test was used to evaluate
the statistical significance of the differences. The prognostic
significance of clinicopathological parameters was determined
using univariate and multivariate Cox regression analysis. In vitro
assay, a statistical analysis was performed using Mann–Whitney0s
U-test for unpaired samples. Statistical analysis was performed
using SPSS software (version 13 for Windows; SPSS, Chicago, IL,
Laminin-332 in oesophageal cancer
Y Baba et al
975
British Journal of Cancer (2008) 98(5), 974–980 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sUSA). A two-sided significance level of Po0.05 was used for all
statistical analyses.
RESULTS
Immunohistochemical expression of laminin-332 in
oesophageal squamous cell carcinomas
In normal oesophageal epithelium, laminin-332 g2 chain was
stained weakly in the cytoplasm of epithelial cells near basal layer.
(Figure 1A and B) In some cancer tissues, the cytoplasm of cancer
cells was stained for laminin-332 g2 chain at levels much stronger
than those in normal BM. Sections with immunostaining signals in
430% of carcinoma cells, which were observed in 55 (44%) cases,
were judged to be positive for laminin-332 g2 chain expression
(Figure 1C and D).
The relationships between laminin-332 expression and clinico-
pathological characteristics are summarised in Table 1. The expres-
sion of laminin-332 was significantly correlated to TNM stage
(P¼0.036). The patients with laminin-332-positive ESCC had a
higher tendency to have lymph node metastasis and deep invasion
than those with negative; however, the differences were not
statistically significant (P¼0.14 and P¼0.15, respectively). On the
other hand, there were no significant relationships between laminin-
332 expression and age, sex, tumour location and histological grading.
Patients with laminin-332-positive tumours had a significantly
shorter disease-free survival and overall cancer-specific survival than
patients with laminin-332 negative tumours (P¼0.0139 and
P¼0.0345, respectively; Figure 2). In univariate analysis, the
significant prognostic factors for predicting both the disease-free
survival and overall cancer-specific survival were histological grading,
T classification, TNM stage, lymph node metastasis and laminin-332
expression. In multivariate analysis, laminin-332 expression was the
independent prognostic factors for predicting the disease-free
survival, but not for the overall cancer-specific survival (Table 2).
AB
CD
Figure 1 Immunohistochemical staining of laminin-332. Original magnification: 200 (A,C,D)  400 (B). (A, B) Expression of laminin-332 in normal
oesophageal epithelium. Laminin-332 is expressed faintly in the cytoplasm of epithelial cells in the basal layer. (C) Positive staining of laminin-332 of ESCC is
indicated. Laminin-332 is clearly shown in the cytoplasm of ESCC. (D) Negative staining of laminin-332 of ESCC is indicated.
Table 1 The relationship between clinicopathological characteristics and
expression of laminin 332
Characteristic
Total
(n¼126)
Negative
(n¼71)
Positive
(n¼55) P-value
Mean age 63.7±5.3 62.8±4.9
Sex 0.81
Male 106 59 47
Female 20 12 8
Tumour location 0.62
Upper 27 13 14
Middle 57 33 24
Lower 42 25 17
Histological
grading
0.75
Well 51 29 22
Moderate 48 26 22
Poorly 27 16 11
T classification 0.15
T1 63 39 24
T2 24 15 9
T3 39 17 22
N status 0.14
N0 62 39 23
N1 64 32 32
Stage 0.036
I4 7 3 0 1 6
IIA 15 9 6
IIB 31 20 11
III 33 12 22
N status indicates lymph node metastasis status. P-values were calculated by using w
2
and Fisher’s exact tests.
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A western blot analysis showed that all five ESCC cell lines
(TE1, TE8, TE9, TE10, TE11) secreted laminin-332 g2 chain
into the conditioned medium, but the secreted level of TE11
was lowest (Figure 3A). In the reduced sample (upper panel), the
155-kDa band revealed the uncleaved laminin-332 g2 chain,
whereas the 105-kDa band revealed the cleaved laminin-332 g2
chain. In the nonreduced sample (lower panel), the upper band
revealed the laminin-332 heterotrimer including the uncleaved
laminin-332 g2 chain, whereas the lower band revealed the
laminin-332 heterotrimer including the cleaved laminin-332
g2 chain.
Expression of EGFR and integrin b4 in oesophageal cancer
cell lines
All five ESCCs expressed EGFR at the protein level. But the band
intensity was different between each ESCCs, and showed expres-
sion at the highest level in TE8 and at the lowest level in TE1
(Figure 3B). All five ESCCs expressed integrin b4 at the protein
level at the approximately same level (Figure 3B).
PI3K activation in oesophageal cancer cell lines
We examined the activity of PI3K pathway by using the
phosphorylated Akt (p-Akt) antibody by western blot analysis.
The band intensity of p-Akt showed expression at higher level in
TE8, TE9 and TE10 than in TE1, TE11 (Figure 3C).
Laminin-332-blocking antibody inhibit PI3K activity and
invasion in TE10
The effect of the laminin-332-blocking antibody on PI3K pathway
was tested in vitro using TE10, which secreted laminin-332 at the
highest level among cell lines and had high PI3K activity in vitro.
After the incubation with the laminin-332-blocking antibodies at
different concentration for 24h, the cells were solubilised. The
laminin-332-blocking antibody suppressed the activation of PI3K
pathway at the concentration of 440mgml
 1 (Figure 4A). The
similar results were achieved by using TE8 and TE9 (data not
shown). Next, we investigated whether the laminin-332-blocking
antibody have an effect on the invasiveness of TE10 in vitro using
the Matrigel-coated invasion chamber. The number of invaded
cells decreased to an approximately half with the laminin-332-
blocking antibody (40mgml
 1) by comparison with non-treatment
or the IgG antibody (40mgml
 1). The PI3K inhibitor (Wortmannin;
100nM) decreased the number of invaded cells to an approximately
quarter by comparison with non-treatment (Figure 4B).
Laminin-332 promotes invasion via PI3K activation in
TE11
The effect of the purified laminin-332 on PI3K pathway was
examined in vitro using TE11, which secreted laminin-332 at the
lowest level. After the incubation with the purified laminin-332 at
different concentration for 6h, the cells were solubilised. The
laminin-332 activated the PI3K pathway at the proportion to the
concentration of laminin-332 (Figure 5A). The number of invaded
cells increased significantly with the purified laminin-332
(0.5mgml
 1) by comparison with non-treatment or control-
purified albumin (0.5mgml
 1); however the addition of the PI3K
inhibitor (Wortmannin;100nM) decreased the number of invaded
cells significantly (Figure 5B).
Effect of PI3K inhibitor on the secretion of laminin-332
in vitro
The relationship between the secretion of laminin-332 and PI3K
pathway was also investigated. The PI3K inhibitor (Wortmannin)
decremented the activity of PI3K pathway in a dose-dependent
manner, and the amount of the secreted laminin-332 into the
medium decreased in proportion to the activity of PI3K pathway
(Figure 6).
DISCUSSION
In the present study, the laminin-332 expression in cancer cells at
the invasive front was seen in 44% of ESCC, and ESCC patients
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Figure 2 (A) Disease-free survival in relation to laminin-332 expression status of ESCC patients. (B) Overall cancer-specific survival in relation to laminin-
332 expression status.
Table 2 Multivariate analysis of disease-free survival and overall cancer-
specific survival in oesophageal squamous cell carcinoma
Disease-free survival Overall survival
Characteristic No. HR 95%CI P HR 95%CI P
N status
N0 (reference) 62 1.00 1.00
N1o 64 4.75 1.67–13.5 0.004 7.75 1.79–24.9 0.006
Histological grading
Well (reference) 51 1.00 1.00
Moderate, poorly 75 2.67 1.39–5.14 0.012 2.34 1.03–5.30 0.038
Laminin 332
Negative (reference) 71 1.00 1.00
Positive 55 2.01 1.18–2.64 0.043 1.93 0.97–3.42 0.062
HR¼hazard ratio; CI¼confidence interval.
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swith its positivity had poorer prognosis than patients with its
negativity. This result was consistent with previous reports about
ESCC (Yamamoto et al, 2001; Fukai et al, 2005) and suggested that
laminin-332 at the invasive front of ESCC might have an important
role in the process of tumour invasion.
Laminin-332 has been reported to have potent cell migration-
promoting activity. Miyazaki and co-workers showed that both
C
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Figure 3 (A) Expression of laminin-332 in the conditioned medium of each ESCCs. All five ESCCs (TE1, 8, 9, 10, 11) secreted laminin-332, but the
secreted level of TE11 is low. In the reduced medium (upper panel), the 155-kD band shows the un-cleaved laminin-332 g2 chain, and the 105-kD band
shows the cleaved laminin-332 g2 chain. In the non-reduced medium (lower panel), the upper band shows the laminin-332 heterotrimer including the un-
cleaved laminin-332 g2 chain, and the lower band shows the laminin-332 heterotrimer including the cleaved laminin-332 g2 chain. (B) Expression of EGFR
and Integrin b4 in each ESCCs. All five ESCCs express EGFR. The band intensity shows the expression at the highest level in TE8 and at the lowest level in
TE1. All five ESCCs express integrin b4 approximately at the same levels. (C) The activity of PI3K pathway was evaluated by Western blot analysis using the
p-Akt antibody. The band intensity of p-Akt shows expression at higher level in TE8, TE9 and TE10 than in TE1, TE11.
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Figure 4 (A) The effect of the laminin-332 blocking antibody at different
concentration on PI3K pathway in TE10 cell line. The laminin-332 blocking
antibody suppresses the activation of PI3K pathway at the concentration of
440mg/ml. (B) The effect of the laminin-332 blocking antibody on the
invasiveness of TE10. The number of invaded cells decreases to an
approximately half with the laminin-332 blocking antibody (40mg/ml) by
comparison with non-treatment or control IgG antibody (40mg/ml). The
PI3K inhibitor (Wortmannin;100nM) decreased to an approximately
quarter by comparison with non-treatment.
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Figure 5 (A) The effect of the purified laminin-332 at different
concentration on PI3K pathway in TE11 cell line. The addition of the
purified laminin-332 activated the PI3K pathway at the concentration of
40.5mg/ml. (B) The effect of the purified laminin-332 on the invasiveness
of TE11 cell line. The number of invaded cells increases with additional
laminin-332 (0.5mg/ml) by comparison with non-treatment or control
Albumin (0.5mg/ml). However, the number of invaded cells decreased with
both additional laminin-332 (0.5mg/ml) and Wortomannin (100nM).
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of human normal epithelial cells and cancer cells in vitro (Miyazaki
et al, 1993; Kariya and Miyazaki, 2004). Laminin-332 has been
reported to interact with integrin a3b1o ra6b4 and activate many
signal mediators such as PI3K, focal adhesion kinase, protein
kinase C, Rac, ERK, JNK and nuclear factor kB, leading to
enhanced cell migration and invasion (Nguyen et al, 2000; Kariya
and Miyazaki, 2004; Nikolopoulos et al, 2005). In particular, the
importance of PI3K activation induced by laminin-332 during
carcinogenesis or tumour invasion has been recently suggested
(Marinkovich, 2007; Waterman et al, 2007). Waterman and co-
workers demonstrated that by in vivo model of human skin
keratinocytes, the binding of laminin-332 to a6b4 integrin
associated and drove tumorgenesis and invasion thorough PI3K
activation in skin squamous cell carcinoma (Waterman et al,
2007). Furthermore, the interaction between laminin-332 g2 chain
III domain and EGFR has been suggested to have a role in PI3K
activation via the action of FYN kinase (Schenk et al, 2003; Guo
et al, 2006; Marinkovich, 2007). Briefly, the interaction of laminin-
332 with a6b4 integrin and EGFR is involved in promoting PI3K
activation and tumour invasion. To our knowledge, as there has
been no article showing the relationship between laminin-332 and
PI3K activation in ESCC, we focused on the relationship between
the PI3K activation and invasiveness of ESCCs in the current
study.
PI3K is a major signalling component downstream of growth
factor receptor tyrosine kinase, and the PI3K pathway regulates
various cellular processes, such as proliferation, growth, apoptosis
and cytoskeleton rearrangement (Cantley, 2002). The aberrant
activation of the PI3K pathway has been widely implicated in
several types of carcinomas (Vivanco and Sawyers, 2002; Fresno
Vara et al, 2004). In our in vitro study, the PI3K activity was
assessed at higher level in TE8, TE9 and TE10 than in TE1 and
TE11. As TE8, TE9 and TE10 secreted laminin-332 at higher level
and also expressed EGFR and integrin b4, which were interacted
with laminin-332, and TE11 secreted laminin-332 at very low level,
the levels of PI3K activity in these ESCCs were understandable.
Similarly in TE1, as this cell line expressed EGFR at very low level,
the secreted laminin-332 might be unable to induce intracellular
signal transduction in vitro. In fact, the addition of the purified
laminin-332 did not activate the PI3K pathway in TE1 in vitro
(data not shown). The laminin-332-blocking antibody deactivated
the PI3K pathway, leading to suppress the invasiveness of TE10,
which secreted laminin-332 at high level and had high PI3K
activity. On the contrary, the addition of the purified laminin-332
activated the PI3K pathway, leading to increase the invasiveness of
TE11, which secreted laminin-332 at lower level and had weak
PI3K activity; however, the accession of the PI3K inhibitor
decrease the invasiveness. These results suggest that laminin-332
could enhance the invasiveness of ESCCs through the PI3K
activation.
In our in vitro study, the deactivation of PI3K pathway using
PI3K inhibitor decreased the secretion of laminin-332, hence the
PI3K activation was considered to be required for the secretion of
laminin-332. Laminin-332 might provide the autocrine positive-
feedback loop via the PI3K activation, contributing the invasive
ability. These results suggest that the inhibitor of PI3K pathway
could be useful as the anticancer therapy for ESCC (Luo et al,
2003). As to the downstream of PI3K pathway, further studies are
needed.
In conclusion, the increased laminin-332 immunoreactivity is
one of the prognostic factors of ESCC. Laminin-332 could provide
the autocrine positive-feedback loop through the PI3K activation,
contributing the invasive ability, hence the inhibitor of PI3K
pathway might be useful as the anticancer therapies for ESCC.
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